Association between the MTHFR A1298C polymorphism and risk of cancer: evidence from 265 case-control studies.

ABSTRACT

Many molecular, epidemiological studies have been performed to explore the association between MTHFR A1298C polymorphism and cancer risk. However, the results were inconsistent or even contradictory. Hence, we performed a meta-analysis to investigate the association between cancer risk and MTHFR A1298C (81,040 cases and 114,975 controls from 265 studies) polymorphism. Overall, significant association was observed between MTHFR A1298C polymorphism and cancer risk when all eligible studies were pooled into the meta-analysis. In further stratified and sensitivity analyses, significantly increased cervical cancer (dominant model OR 1.46, 95 % CI 1.13-1.90; AC vs. AA OR 1.48, 95 % CI 1.13-1.92) and lymphoma (dominant model OR 1.22, 95 % CI 1.04-1.44; recessive model OR 1.66, 95 % CI 1.15-2.39; CC vs. AA OR 1.75, 95 % CI 1.21-2.53) risk were observed in Asians, and significantly decreased colorectal cancer risk was found in Asians (recessive model OR 0.75, 95 % CI 0.59-0.96; CC vs. AA OR 0.77, 95 % CI 0.60-1.00). In summary, this meta-analysis suggests that MTHFR A1298C polymorphism is associated with increased cervical cancer and lymphoma risk in Asians, and MTHFR A1298C polymorphism is associated with decreased colorectal cancer risk in Asians. Moreover, this meta-analysis also points out the importance of new studies, such as oral cancer and chronic myeloid leukemia, because they had high heterogeneity in this meta-analysis (I (2) > 75 %).